Related Experiment Video
Updated: May 12, 2026
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Predicting PML in natalizumab-treated patients: can we do better?
Tobias Derfuss1, Ludwig Kappos
1Department of Neurology, University Hospital Basel, , Basel, Switzerland.
Journal of Neurology, Neurosurgery, and Psychiatry
|April 23, 2013
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Disability accrual in primary and secondary progressive multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry·2023
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.
Neurology(R) neuroimmunology & neuroinflammation·2023
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Neurology(R) neuroimmunology & neuroinflammation·2023
Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.
Journal of neurology, neurosurgery, and psychiatry·2026
Iatrogenic cerebral amyloid angiopathy: a scoping review.
Journal of neurology, neurosurgery, and psychiatry·2026
Associations of self-reported and objectively measured physical activity and amyotrophic lateral sclerosis risk.
Journal of neurology, neurosurgery, and psychiatry·2026
Cerebrospinal fluid haemoglobin as a monitoring biomarker for secondary brain injury after aneurysmal subarachnoid haemorrhage: prospective international multicentre validation study (HeMoVal).
Journal of neurology, neurosurgery, and psychiatry·2026
HLA-dependent association between EBNA1 antibody levels and disability progression in multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry·2026
Recombinant factor VIIa for spontaneous intracerebral haemorrhage: a meta-analysis of randomised controlled trials.
Journal of neurology, neurosurgery, and psychiatry·2026